Skin Res Technol. 2020;26:301–307. wileyonlinelibrary.com/journal/srt
|
301
Re cei ved: 9 A ugu st 2 01 9
|
Ac cept ed: 5 S ep te m b er 2 019
D O I : 10 .1111 /s r t .1 2 8 0 0
ORIGINAL ART ICLE
In viv o det ec tio n o f c han g es i n cu taneous caro t e noi ds a f t er
che mo th erap y u si ng sh i f ted e x ci tati on r eson anc e Raman
di f ferenc e and fluor esc enc e spec trosc op y
Sora Jung 1 | Maxim E . Dar vin 1 | Johannes Schleusener 1 | Gisela Thiede 1 |
Juergen Lademann 1 | Marcel Braune 2 | Mar tin Maiwald 2 | B ernd Sumpf 2 |
Günther T ränkle 2 ,3 | D unja K ut zer 4 | F elia Elban 1 | Harald F uss 4
1 De p a r t m e nt of D e r m at o lo g y , Ven e r ol o g y
an d A l l e r go lo g y , Ce n te r of E x p er i m e nt al a n d
A p pl i e d Cu t an e o u s Ph ys io l o g y, Ch ar i té –
Un i ve r s it ät sm e d iz in B e r l i n , B er l i n , G e r ma ny
2 Ferdinand-Braun-Ins titut , Leibniz -Inst itut
für Höchst freq uenz technik, Berlin , Germany
3 Fak u lt ät I V , T e c h ni s ch e U n iv er si t ä t B er l i n ,
B er l i n , G e r ma ny
4 D ep a r t m e nt H e m ato l o g y a n d O n c ol o g y ,
He l io s K l i ni k u m B a d S aa r ow, Ba d S a a ro w,
G er m any
Correspondence
S or a J u n g , D e p ar t m e nt o f D e r ma to l og y,
V en e r ol o g y a nd A ll e r go l og y, Cen te r of
E x p e r im e n t a l a nd A pp l i e d Cu t an e o u s
Phy s io l og y, Cha r i té – U n iv e r si t ä t s m e d iz in
B er l i n , Ch a r i té p la t z 1, 1011 7 B e r l in ,
G e r m a n y.
Email: sor a_ [email protected]
F unding information
Einstein Foundation Berlin
Abstr act
Back ground: V a r iou s cu t a ne o us tox ici ti es u n de r ch em ot he r a py in di c ate a l oc al ef -
fe c t of ch e mot h er a py by se cr et io n af ter s y s tem ic a pp li c at io n. H e re , cha nge s i n th e
fl uo re s cen ce an d R a ma n sp e c t r al p ro p er t ie s of t he s t r at um corn e um su bs e qu ent t o
int r aven ou s ch em ot he r apy we re a ss es se d .
Methods: T we nt y h e al thy su bje c t s a nd 2 0 c an ce r p at ie nt s u n de r goin g c he m oth e r apy
were included. Meas urement time poi nts i n c ancer pa t ients were before the first
c ycl e of che m oth e r apy ( T base ) an d im me di atel y af te r int r aven ou s ap p lic ati on of t he
chemotherapy ( T 1 ) . Healthy subj ec t s were measur ed onc e withou t an y fur ther in ter -
ven tion. Measurements were conducted usin g an individua lly manufac tured system
cons is ti ng of a ha nd he l d p rob e a n d a w avele ng t h-tuna b le d io de las er -b as e d 4 8 8 n m
SH G li ght s o urce . H er eby , ch an ge s in b ot h sk i n fl u ore s cen ce a nd shi f ted excit a -
tio n re s on an ce R am an d if fe re nce s p ec t ros copy (S ERR DS) c a rote n oid si gn als we re
assessed .
Res u lt s: H e a l t hy s u b j e c t s s h o w e d s i g n i f i c a n t l y ( P < . 0 01) h igh e r m e an con cent r at io ns
of c a rote n oid s co m pa re d to c an cer su bj ec t s at T base . A n in c re ase i n f l uo re sce n ce i n -
t e n s i t y w a s d e t e c t e d i n a l m o s t a l l p a t i e n t s af t e r c h e m o t h e r a p y, e s p e c i a l l y a f t e r d o x o -
ru bi cin i nf usio n . Fur th e rm o re, a d e cr ea se i n th e c a rote no id co nce nt r ati on i n th e sk i n
af te r ch e mot h er a py wa s fou n d.
Conclusion : The SER R DS bas ed n oni nvas ive dete c ti on c an b e use d as an ind ire c t
quanti tative assessment of fluorescent chemotherapeutics. T he low er caroteno id
SER RD S inte nsi ti es at T bas e might b e du e to c a n cero us d is ea se s an d co -me di c at ion .
KE Y WO R D S
c a rot en o id s , ch e mo t he r a py , f l uo r es ce n ce , R am a n di f fe re n ce s p ec t ro s co py , s hi f t e d exc it at io n
resonance
T hi s is a n o p e n a cce s s a r t ic l e un d e r t h e te r m s of t h e C re a t iv e C om m o ns A t t r i b u t io n L i ce ns e , w hi c h p e r mi t s us e , d is t r i b ut i o n a nd r e p r od u c ti o n i n an y me d i um ,
pr ov i d e d t he o r i gi n al w o r k is p r op e r l y c it e d .
© 20 2 0 T he A u t h or s . Skin Researc h and T echnology Pu b l is h e d by J o hn W il ey & S o n s Lt d .
302
|
JUN G e t a l .
1 | INTROD UC TI ON
Cu t a n e ou s toxi ci t ie s co un t t o t h e mo s t fr e qu e nt si de ef f e c t s du ri n g
chemotherapy . 1,2 P rev i ou s s t u di e s s how ed th at i nt r ave n ou sl y app l ie d
ch e mo th e r a p eu t ic s c a n b e fo un d w it h in t h e s we at b e in g s e cr et ed t o
the skin sur face. The chemotherapeutic s subsequently spread on the
sk i n su r f a ce as if to p ic a ll y ap p li e d an d re- p e n e t r a te in to th e up p e r sk i n
laye r s . 3 Here, they can lead to r adical formation and inflammat or y or
tox ic sk in ef f e c t s , inc lu d in g deve l op m e nt of p al m ar -p l an t a r er y th r o dy -
s ae s t h e si a, al s o kn ow n as a h an d-fo ot sy n d ro m e. 4 -1 0
Th e s k in of he a lt hy vo l un te e r s , e sp e c ia ll y t h e s t r at u m co r ne u m
laye r , usu a ll y con t a in s a h ig h con ce nt r at i on of ant i oxi da nt s . A mo n g
th e m ar e c a rot en o id s , vi t a mi ns , a nd e nz y m e s , wh ic h for m a n ant i ox -
id an t ne t w or k an d s er ve as a pa r t of th e bo d y 's p ro te c t i ve sy s te m
ag a in s t f re e r a di c a ls . Re ce n t s tu d ie s s ho w th at c ar ote n oi ds s e r ve a s
ma r ker s ub s t a n ce s of t h e e nt ir e an ti ox id an t s t at u s of t h e e pi d er m is
in viv o 11 ,1 2 an d t h e k in e t i c s of t h e i r de g r a da t i o n in th e sk i n s h ow th e
int en si t y of inf l u en c in g s t re s s f a c to r s . 13
Th e k i n et i c s of inve r s e p e ne t r at io n of d oxor u b ic in o n t h e s k in
sur fa ce were descr ibed previousl y . 3 I t w as fo un d t hat 3 0 m i nu te s t o
1 hour after s ystemic administration af ter chemotherapeutic infu -
sio n , f l uo r es ce n ce si gn a ls of d oxo r ub i ci n we re d e te c t ab l e on th e s k in
sur f a ce. 3 T hi s le a d s to t h e co nc lu si o n t hat d oxo r u bi ci n , li ke c ar ot -
en o id s a nd vit a mi n E , to o , is s e cr e te d to t h e s k in s u r f ac e wi t h t h e
s we at , sp re a ds th e re , an d th en pe n et r a te s into th e st r at u m cor ne u m
like topic all y app lied. 14 T his result also explains why th e dermal side
ef fe c t s as s oc ia te d w it h s y s te mi c ad m in is t r at i on of doxo r u bi ci n oc cu r
ma in l y in th e p a lm s of t h e h an d s an d t h e s o le s of t h e f e et . T he h ig h -
es t sw ea t gl a nd d e ns it y is p r e se nt a t t he s e sk i n si te s 15 so t h at t h e
pr o po r t io n of e s c a p in g d oxo r u bi ci n i s h ig h e s t h e re a s we l l. T h e h o r ny
laye r i s te n t o t we nt y t im e s t h ic ker on th e p a lm s a n d s ol e s of th e fe et
th a n o n th e o th e r a r e as of t he sk i n, pr ov id in g an i d ea l re se r vo ir fo r
the absorption of sweat -deriv ed substances, such as chemothera -
pe u t ic s in hu m an sk i n. D ep e n d in g o n t h e d e sig n ate d c h em ot h e r ap y
sc h ed u le a nd d os e, m ul t ip l e c ycl e s of c h em ot h e r ap y c an c a us e an
accumulation of chem othera peutic subst an ces 16 r e so l v in g in tox i c
lo c a l ef fe c t s on th e sk in . Ho weve r , th e sp e ci f ic qu a nt it i es an d d y -
na mi c s f or d if f er e nt c he m ot h er ap e u ti c s a re n ot f u ll y u n de r s t o od . 17
Many chemotherap eutics are R aman- ac tive subst ances, but their
di re c t d et e c t io n on th e s k i n is ha r dl y p o ss ib l e d u e t o t h ei r low con -
cen tration and superpos ition with the skin R aman spec trum. 1 8 ,19 I n t h e
c as e of d oxo r ub i ci n , ab s or p ti o n ba n d s in t h e r a ng e of 4 4 0 -5 2 0 nm 20
a n d f l u o r e s c e n c e in t h e r a n g e of 52 0 - 6 3 0 n m 21 ar e k n o w n . T h i s m e a n s
th at t h e e xci t a ti o n a r ou n d 4 8 8 nm r es o na nt l y exc it es n ot o nl y t he c a -
rot enoids bet a-carot ene and lycopene 22 b u t al so a d oxor u b ic in f l uo -
re sce nce si gna l 23 , 24 in the sk in . Th u s, on th e one ha nd , th e doxor u b ic in
fl u or e s ce nt sig n al a c t s as a ba c k g ro u n d sig na l fo r th e R a ma n sig n al .
O n t he o th e r h an d , t hi s f lu o re s ce nt s ig na l m ake s it p o ss ib l e to d et e c t
doxo r u bi ci n ver y se ns it i ve ly in hu ma n sk in un d e r in vivo co nd i ti on s .
No n inv as ive ref l e c t i on sp e c t r os co py was us e d in a p r ev io u s
s tu d y to inve s t ig at e t h e d e cr e as e in cu t a n e ou s ca rot en o id s a s a
result of increase d skin r adic al formatio n following intravenous ad -
mi ni s t r at io n of c he m ot h er ap e u ti c a gen t s t o t he p at i en t ' s pa lm s . T h e
result s clearl y showed the signific ant decrease in cut aneo us carot -
enoids in all intravenously a dministered chemotherap eutic agents . 25
Th is c le a r d e c re as e is d ete c t a b le us in g eve n l e s s s e ns it i ve t ec h ni qu e s
such as re flection spectrosco py . 22 T h e r e f o r e , a n o ve l d i a g n o s t i c s y s -
te m wou l d b e n ot o n l y o f g r ea t im p o r t a nc e f o r th e d ir e c t d et ec t io n
of d oxo r ub i ci n o n t he s k in b ut a ls o fo r in d ir e c t d ete c t io n of a w h ol e
range of other chemotherapeutic agen ts by measuring their influ -
ence on cutaneous c arotenoids.
I n o r d e r to b e a b l e t o qu a n t i t a t i v e l y d e t e r m i n e s m a l l c h a n g e s i n t h e
R a m a n s i g n a l i n t e n s i t y o f c u t a n e o u s c a r o t e n o i d s i n v i v o , a f l u o r e s c e n c e
ba c k g ro u n d su bt r a c t io n p ro ce d ur e s h ou l d b e p e r fo r m ed . Th is c an be
do n e by t a k in g a d v an t a ge of t he f lu o re s ce n ce p h oto -b l ea c hi ng ef f ec t
b y p r o l o n g e d e x p o s u r e o f t h e s k i n w i t h t h e r e f e r e n c e l i g h t . 26 How ev er ,
this meth od is tim e-consuming and did n ot provide complete subtr ac -
tion of the fluorescence background. 27 A f u r t h e r m e t h o d i s s h i f t e d
exc it at io n r e so n an ce Ra ma n dif f er e n ce s p e c t r os co py (SER R DS ), w h ic h
pr ov id e s c ha ng es of t he exc it at io n w avel e ng t h by ab o u t 0. 4 n m , s o t ha t
th e R a ma n si gn al s sh if t al o ng w it h t h e e xc it a t io n w ave l en g th , w h il e t h e
fl u or e s ce nce b a nd s re m ai n al m os t co ns t an t . B y su bt r a c t i ng t h e t wo
re co rd e d s p e c t r a f r om ea c h ot h er , t he f l u or e sc en ce ba c k g ro u n d is e f -
f e c t i v e l y s u b t r a c t e d , a n d t h e c a r o t e n o i d c o n c e n t r a t i o n c a n t h e n b e d e -
termined by integr ating the correspo nding R aman ba nds. T he S ERRDS
de vi ce o pt i mi zed f or in v ivo m e a su re m en t s o f c a rot en o id s in h u ma n
sk i n w as re ce nt l y deve l o p ed by th e Ferd in a n d-B r a u n- In s t it u te 28 with
su pp o r t of the Ei ns t ei n Foun d at io n .
He re , cha nge s in t h e fl uo re sce nce a n d SER RDS s ign al i nten sit ie s
before and a f ter intravenous chemo therapy were a ssessed i n vivo in
c a nce r p at i en t s .
The assessment s within this s tudy aimed at deter mining changes
in t h e c a r ote n oi d co n ce nt r at io n of th e s k in a s we ll as d ete c t in g d if -
ferent chemotherapeutics by f luorescenc e changes af ter intra ve -
nous applicatio n.
2 | MA TERIA L S A ND ME TH ODS
2 . 1 | Measuremen t system
A miniaturi z ed measurement system based on SERRD S 28 wa s us e d for
the assessment of chang e s in cut aneous c arot enoids and fluorescence
sig n al s on th e sk i n su r f a ce i n vi vo. Th e s ys te m us e s a m e as ur i ng s p ot
dia m et e r of 3 mm a n d a di od e las e r - ba s ed 4 8 8 n m S H G l ig ht s o u rce
pr ov id in g t wo e xci t a ti o n wave l e ng t hs λ 1 = 487 .2 n m a nd λ 2 = 487 .6 n m .
He r e, th e f l u or e s cen ce ba c k g r ou n d c a n b e s e p ar a te d f ro m t h e R a m an
pe a k s . T h e s y s te m wa s c a li b r ate d to a de te c ti o n li mi t of 0 .0 3 nm o l g −1
b e t a - c a r o t e n e p e r g r a m o f s k i n a n d w a s d e s c r i b e d i n d e t a i l p r e v i o u s l y . 28
Th e c a rote n o id s' sign a l was re cog n iz a bl e at app r ox . 15 2 5 cm −1 . 22
2 . 2 | Stu dy d esi gn
A tot a l of 20 h e al t hy su bj e c t s a nd 2 0 c a n ce r su bj e c t s age d f ro m
4 3 to 77 wer e en ro ll e d in th e st u d y , wi t h ea ch su bj e c t gr o up
|
303
JU N G e t a l .
in c lu d in g 10 ma le a n d 10 f em a l e s ub j ec t s o f s k in t y p e I- I II . C an ce r
subject s suffered from pancreatic c arcinoma (25 %), mamma carci -
no m a (15 % ), n o n-H o d gk i n's l y mp h o ma ( 10% ), l ip o s ar co ma ( 1 0% ),
rhabdomyo sarcoma ( 5 %), prost ate c ancer (5 %), multiple myeloma
( 5 %), hyp ophar yngeal c arcinoma (5 %), and aden oc arcinoma of th e
ova r y (5%) a n d of t h e ce c um (5%) an d m et as t at ic ad e n oc ar ci n om a
of un k n ow n pr i ma r y (5%). Th e c he m ot h e r ap ie s i n cl ud e d ( pe -
g ylated liposomal- ) doxorubicin, epir ubicin, dac ar bacin, vincris tin,
cycloposphamid, Ifosphamid, topotecan, irinotecan, 5- fluorour a -
cil , (na b - ) p a cl it a xel , do ce t a xe l , c a rb o p la ti n , an d ge mc it a bi ne a n d
wer e ap p li e d i n an am b u la nt se t ti n g. T he p at ie nt - re la te d ap p li ed
ch e mo th e r a p eu t ic s ar e su m ma r ize d i n T ab l e 1. All s ub je c t s did
n ot r e ce i v e a n y c h e m ot h e r a py w i t h i n t h e l a s t 4 w e e k s p r i o r to t h e
Tb a se me as ur e me nt s . The mai n exc lu si on cr ite r ia wer e a ny t y pe of
cu t a n eo u s t oxi ci t y , ec zem a , or ot he r re l ev an t s k in di se a se w it hi n
the measuremen t area.
Me a su re m e nt s in c a n ce r su b je c t s we r e t a ken o n ce b e fo re s y s -
temic intravenous administ ration ( T base ) of the c hemotherapeutic
age nt an d a se c on d ti me im me d ia te ly af te r s y s te m ic ad mi ni s t r at io n
of the chemotherapy ( T 1 ). T h e me a su re m e nt s wer e c ar r i e d ou t on
both palms at each thenar eminence with f ive me asuremen t s per
ti m e p oi nt a nd m e as u ri n g ar e a .
He a lt hy su bj e c t s wer e me a su re d at on e ti m e poi nt w it h ou t any
fu r t h er i nte r ve nt i on a n d m ea su re m e nt d at a co m p ar e d to t ho s e of
c a nce r s ub je c t s a t T base .
Su b se q u en tl y , t he me a su re d Ra m an sp e c t r a wer e an al y ze d
for measurement quality and the p resence of caroteno id- related
Raman bands . T he corre spondin g SERRDS intensity was c alculated
by int egra ting the Raman sig nals arou nd the peak at 15 25 cm −1 a t
an e xci t a ti o n wave l e ng t h of 4 87 . 2 an d 4 87 .6 n m a n d wa s u se d f or
th e as s e ss m e nt of c a rot e no id co n ce nt r a t io n in t h e s k in . T h e me a n
of t he SER RD S in te ns it ie s of a ll mea su re m e nt s f ro m o ne me a -
su re m en t ar ea w as c a l cu la te d. I n ad d it io n to th e S ER RD S re su lt s ,
the fluorescence intens ity at identical position (peak at 5 26.3 nm:
exc it at io n wavel e ng t h 487 . 2 nm , Ra ma n shi f t 15 25 cm −1 ) w a s
cal culated.
The applied chemotherapeutics in 18 out of 20 patien t s could b e
divided int o t wo major groups according to their main ac t ive in gredi -
en t s , o n t h e on e h an d , a c t i ve in g re d ie nt s f ro m t he g r ou p of a nt h r a c y -
cl in e s a n d o n t h e ot h e r h an d , th e a c ti ve ing r ed ie nt s fr om th e g r ou p
of a lk a l oi ds ( T ab l e 1). T wo pa ti e nt s r e cei ve d bot h an t hr a c ycl in e s a n d
al k al oi d s. T hi s assi gn m e nt was us e d in par t s of th e eva l ua ti o n .
2 . 3 | Ethic a l ap pr oval
Pr io r t o in it i at io n of t h e s t u d y , a p pr ova l by th e i n de p e n de nt Eth ic s
Co m mi t te e of t h e St at e O f f ic e of H ea l t h an d S o ci al Af f ai r s B e r li n
(L a G e So) w as o bt ai ne d . T h e s t u d y wa s re g is te r ed at t he Eu r op e a n
Dat ab a nk o n M e di c a l D ev ice s (E ud a me d N o. C IV 1 5- 0 3- 013265)
an d w as c on d u c te d a cc or di n g to t h e p ri n ci p le s of t h e D e cl a r at io n
of Hel si nk i ( 1 996) a nd G oo d Cl in ic al Pr a c t i ce Gu id e li ne s . Al l subj e c t s
provi ded written inf ormed c onsent.
2 . 4 | S tatistic al analysis
T h e d e s c r i p t i v e a n d s t a t i s t i c a l a n a l y s i s o f t h e o b t a i n e d d a t a w a s c o n -
du c t e d u si ng IB M SP SS vs 22 . An a ly si s of SE RR D S v al u e s w a s s ub -
je c t to M a nn -Whi t ne y U tes t , in which P -v al u es of l e ss th an .0 5 w er e
con si d er e d to i nd ic ate s t at is t i c a l sig n if i c a n ce.
3 | RESUL TS
3 .1 | Fluor escenc e analysis
Th e me an fl uo r e sce n ce sign a l i nte ns it y inc re a s ed by 1. 2 ± 0. 3 a t T 1
sh ow in g a n in cr e as e i n 1 4 o u t of t he 2 0 c a n cer s u bj ec t s .
A s s h ow n in F i gu re 1, t h e ma jo r it y of p at i e nt s sh owe d a n in -
crease in mean fluor escenc e in tensity after the end of chemother -
ap e u ti c t re at m e nt at T 1 , while the fluorescenc e intens ity in some
pat i en t s re m ai ne d al m os t u nc ha n ged ( pa ti en t s 6 an d 12) an d eve n
de c re a se d in fo u r p at ie nt s (p at ie n t s 1, 3 , 13 , a n d 15 ). T h e hi gh -
es t in c re as e s i n f lu o re s ce n ce s ig na l we re se e n i n pa t ie nt s re c ei v -
in g doxo r u bi ci n , a m em b e r of t h e an th r a c yc li n e gr o up, w h ic h is
known for generating it s own fluorescence, which was expected
to in c re a se t h e f lu o re s ce n ce of t he s k in w i th i n t h e s e inve s t ig a -
ti on s . Ac cor d in gl y , a n ave r age i n cr e as e of 1. 3 ± 0 .1 w as a ss e s se d
fo r p at ie nt s r e cei v in g d oxo r ub i ci n (p at i en t s 4, 9 , 17 , 19 , a n d 2 0 ). A
T A B LE 1 Chemotherapeutics applied in the indivi dual patien ts
Patien t number Chemotherapeutic substance
1 Irinotecan/folinic acid/ f luorour acil
2 Paclitaxel
3 Do ce t a xe l
4 Cy clop hosphamide/ d ox orubicin/vincristine
5 Do ce t a xe l
6 Bor tezomib / peg y lated liposomal doxorubicin
7 Carb oplatin / paclita xel
8 Pegy lated liposomal do xoru bicin
9 Cy clop hosphamide/ p eg ylated liposomal
doxorubicin/ vin cristin e
10 Paclitaxel / cetuximab
11 Protein- b ound paclita xel/ gemcitabin e
12 Protein- b ound paclita xel/ gemcitabin e
13 Ifosfamide/ e pirubicin
14 Protein- b ound paclita xel/ gemcitabin e
15 Protein- b ound paclita xel/ gemcitabin e
16 Protein- b ound paclita xel/ gemcitabin e
17 Doxorubicin/ daca rbazine
18 Cy clop hosphamide/ e pirubicin
19 Doxorubicin/ d aca rbazine
20 Doxorubicin/ daca rbazine
304
|
JU N G e t a l .
mi no r m e an i n cr e as e in f l uo r es ce n ce by a f a c t or of 1 .1 ± 0 .1 w as
obser ved in patient s receiving p eg ylated lip osomal d ox orubicin
(Caelix ® ) ( pa t ie nt s 6 an d 8). O n e ex p l an at io n fo r t hi s may b e a
minor rele ase of doxorubicin in the lipos omally en capsulated for m.
Patien ts treated with t he doxorubi cin- related chemotherapeutic
age nt e p ir u bi ci n , w hi ch i s al s o kn ow n to h ave a utof l u or e s cen t
pr o pe r t ie s , a ls o s how ed a s m al l in c re as e i n fl u or e s ce nce ( p at ie nt
18 ) . T h e s i n g l e , d i s t i n c t d e c r e a s e i n f l u o r e s c e n c e w a s f o u n d i n o n e
pa ti e nt of t he a nt h r a c yc li ne g ro u p af te r tr e at m e nt wi t h ep i r ub ic in
(patient 13) , which c an only be explain ed by dif feren ces of t he in -
di v id ua l m et a b o li sm a nd k in e t ic s .
Patien ts who rec eived chemotherapeutics o f the alkalo ids grou p
(eg , p a cl it axe l , do ce t a xe l , n a b-p a b li c t a xel , or to p ote c a n) s h owe d a
me a n inc re a se in th e flu o re s ce n ce of t h e ski n by a f ac to r of 1 . 3 ± 0 . 2
de s pi te t he l ac k of f l u or e sc en ce of th e dr u g s t he m se l ve s w i th i n t h e
me a su re m e nt ti m e po in t s 1 ho u r af t er te r m in at io n of th e in fu si o n of
the chemotherapeutic agents. Patien t s treated with the chemo t her -
apy d r u g na b -p ac li t a xe l (ab r a x a ne , p at ie nt s 11, 1 2 , 1 4 , 15, a n d 16)
sh owe d ha rd l y a ny c h an ge in th e fl u or e sc en ce sig n al at th e en d of
tr e at m en t (me a n ch a nge 1 .1 ± 0.1 ) .
Conflic ting result s of skin fluore scence obser ved in t wo pa -
ti e nt s of th e al ka l oi ds g ro u p (p at ie nt s 1 an d 3) af te r ad mi ni s t r at io n
of th e c he m ot h er apy w it h f l u or ou r a ci l an d d o cet a xe l, c an o nl y b e
ex p la in e d by t h e in d iv i du a l me t a b o lis m a n d ki n et i c s .
3. 2 | S ERR DS an al ysis: C ar otenoi ds
He a lt hy su bj e c t s s h owe d a m e an S ER RD S c ar ote n oi d i nte n si t y at
1 136 .4 a . u ., w hi c h wa s sig n if i c a nt l y hi gh e r ( P < . 0 01) t ha n c a n ce r
su bj e c t s b efo r e ch e m ot he r a py at T base w i t h a m e a n S E R R D S c a r o t -
en o id i nte ns it y of 4 35. 6 a .u . (F ig u re 2).
A s s ho wn i n Fi g ur e 3 , t h e i nte ns it y of t he SERR DS sign al s ,
represe nting the concentration of ca rotenoids, decrease s in
th e ma jo r it y of pat ie nt s ( 13 out of 20 ) af te r ad mi n is t r at i on of
chemotherapy .
Pa ti e nt s r ec ei v in g a nt h r a c yc li ne s sh owe d a m e an de c re a se in
SER R DS sig n al i nte n si t y of c a ro te no id s of 32 . 8 a .u ., w h il e a m e an
decrease of SERRDS signal intensit y in patient s re ceiving alk aloids
wa s fo un d a t 21. 6 a .u . (F ig u re 4).
Fur t he r m o re , it c a n b e s t ate d t h at a h ig h e r d e c re as e in S ER R DS
int en si t y c a n b e o bs e r ve d i n pa ti e nt s w ho have a lr e ad y b e e n c he -
mo th e r a p eu t ic al l y t re at e d at an e a r li er s t a ge co m p ar e d to pat i en t s
re ce iv i ng c h em ot h e r a py fo r t he f ir s t t i me .
Th e de g re e of ca rot en o id de g r a dat i on , wh i ch cor r e lat e s wit h th e
de c re a se i n SER R DS in te ns it y , a pp e a r s to re fl e c t t h e in di v id u al s t ate
of t he s k in's a nt iox i da nt p r ote c t i on s y s te m , w h ic h may b e d e p en d e nt
on the st age of tumor dev elopment , number of prior chemothera -
peutic treatme nts , and lifest y le, inclu ding an antioxidant s cont aining
diet.
FIG U R E 1 M e a n ch a nge s i n no r m al ize d f lu o re s ce n ce in te ns it ie s
in e a ch s ub je c t at b as e m en t me a su re m e nt s ( T base , b la c k sq u a re s)
an d af te r co m p le t io n of in tr aven o us a d mi n is t r at i on of r e sp e c ti ve
chemotherapeutic a gen t ( T 1 , g r ay t ri an g le s). S how n a re t h e
c al c ul ate d m e a n va lu e s of t h e f lu o re s ce n ce in te nsi t ie s of t h e l ef t
an d r ig ht t h e na r e mi ne n ce
FIG U R E 2 B ox p l ot of S ER RD S c a rot en o id s ig na l in te ns it ie s i n
c a nce r s ub je c t s p r i or to t h e f i r s t c yc l e of ch e m ot he r a py at T base an d
he a lt hy s ub je c t s s h ow in g a sig n if i c a nt d if fe r en ce . C an ce r su b je c t s
re ce ive d n o c he m ot h e r apy 4 w e ek s p r i or to t h e m e as ur e me nt s at
T base
|
305
JU N G e t a l .
4 | DI SCUSS I ON
In su m ma r y , t he a pp l ie d SER R DS m e asu r em e nt s sh owe d exc re t io n
of i nt r ave n ou s ch e mo t he r a p eu t ic a ge nt s o n t h e sk i n s ur f a ce by si -
mu lt an e o us l y ana l y z in g th e ca ro te no i d ant iox id a nt s and t he f lu o re s -
cen ce in t h e sk i n . T he m e a su re m en t s ys te m co ul d b e u se d f o r t he
indic ation to initiate a prevention st rateg y of cutan eous toxicities in
th e f or m of t op ic al a p p li c at io n of a nt iox i da nt s . 2 9, 3 0
Th e re s ul t s obt ai n ed s h ow th at s om e of th e f lu o re s ce n ce-a c -
tive chemotherapeutic agents, for example, doxorubic in or epi -
r ub ic in c a n b e de te c t e d d ue to en ha n ce d s k in f lu o re s ce n ce a s
expected. 31
The direc t d etec tion an d ide ntific ation of all fluore scence- f ree
ch e mo th e r a p eu t ic age nt s in th e ski n usin g SER R DS was not
ob s er ve d wit h in th is st u d y and ca n be sub je c te d to f u r t he r
in vestigati ons.
Nev er theless, indirect measuremen t of chemotherapeutic
age nt s o n t h e sk i n su r f a ce is p o ss ib l e by S ER R DS m e as ur e me nt s of
epider mal carotenoid antioxidant s, which are diminishe d by interac -
ti on wi t h t h e c he m ot h er ap e ut i c a ge nt s . T hi s co nf i r ms th e a ss u mp -
ti on t ha t t op i c al l y a p p li e d c h em ot h e r ap e u ti c age nt s th at re a c h t h e
sk i n sur f a ce t h ro u gh s y s te mi c ad m in is t r a ti on by s we at o r se b um a re
FIG U R E 3 M e a n ch a nge s i n
SER R DS s ig na l i nte ns it i es of c u t a ne o u s
carotenoi ds at basement meas urements
(b la c k s qu a re s) an d af te r in t r ave no u s
ch e mo th e r a py a dm in is tr a t io n ( g r ay
tr i an g le s). Sh ow n a re t h e c a l cu la te d
me a n va l ue s of t h e S ER R DS c a ro te no id
int en si t ie s of t h e le f t an d r ig ht t h e na r
eminence
FIG U R E 4 M e a n SE ERD S c a rot e no id s ig na ls i n p at ie nt s
re ce iv i ng c h em ot h e r a py wi t h an t hr yca c li ns a n d al k al o id s . Bo t h
gr ou p s sh ow a n ove r al l d ec r ea s e in S ER R DS si gn a l int en si t ie s . T h e
er r or b a r s re p r es e nt t h e 95 % co nf id e n ce in te r v al
306
|
JU N G e t a l .
ab l e to in d u ce ox i da ti ve s t re s s c on d it io n s i n t h e s k in . 32 The gener -
ate d r a d ic al s re a c t as top ic al l y a pp l ie d w it h th e s k in's a nt iox i da nt s
in t h e s t r at u m co rn e u m , wh ic h a re s ub s e qu e nt l y de c re a se d . B y r e -
du ci n g t h e l eve l of ant iox i da nt s , t h e p r ote c t i ve f u n c t i on of t he sk in
is wea ke ne d an d t he in d u c t io n of sk in da m age , inf l am m at io n , or sk i n
tox ic it y , a s s h ow n fo r t h e h an d -foot s y n d ro m e, c a n i nc r ea s e w it h
each chemo ther apeutic cycl e.
The distinct varia tion in carot enoid concen tration bet ween sub -
je c t s i s du e to inte r i nd i vi d ua l d if fe r en ce s i n d ie t a r y b e hav io r a n d
lif e s t y le , as k now n f ro m a num b e r of oth er s t u di es co n du c te d in th is
field. 3 3-3 8
Fur t he r m o re , it c a n b e s t a te d th at c an ce r su b je c t s a lr ea d y s ho w
sig ni f i c a nt l y l owe r SER RD S ca rot e no id inte n si ti e s befo r e c h em o -
th e r a py t re at m e nt co m p ar e d to h e al t hy su bj e c t s . T hi s c a n b e du e
to the cancerous di sease i t self and associa ted emo tional burden and
stress, 3 9 - 41 due to co- med ica tio n or ev en to pri or che mo thera peuti -
c al t r e at m en t s a t an e a r li er s t a ge.
The level of c aroteno id degradation after chemotherapy that
cor r e la te s w it h th e de c re a se in SE RR D S in te ns it y a p p e ar s to r e -
fl e c t t h e in di v id u al s t ate of th e s ki n's ant i oxi d an t pr ote c t i on s y s -
tem, whic h ma y be dependent on the stage o f tumor dev elopment,
number o f prior chemotherapeutic treatmen t s , lif est yle, and anti -
oxi da nt di et .
Int erestingly , patients who rec eived chemotherapy for the firs t
ti m e sh owe d a h ig he r i nc r ea s e in f l uo r es ce n ce i nte ns it y . T h is m ay
be du e to the f ac t th at wit h ea c h che m ot he r a py c ycl e , dep e n di ng on
do s ag e an d c ycl e int er v a ls , a po r t io n of th e che m ot h e r ap e u ti c age nt
re ma i ns i n t he s k in , w h ic h se r ve s a s a re s e r voi r a n d t hu s le a d s to
increased baseline fluor escence intens it y .
Th is me as u re m en t s et t in g co u ld be of us e i n f u tu r e s t u di es in -
v e s t i g a t i n g , f o r e x a m p l e , d i s r u p t i v e e f f e c t s o n t h e s k i n b a r r i e r s u b s e -
quent to chemotherapy . Changes in the lipi d/k eratin concen tration
of t he s t r a tu m co r n eu m af te r co m p le t io n of t h e s ys t em i c ad m in is -
tr at io n of th e c he m ot h e r ap e u ti c a ge nt s c a n se r ve a s a n a d di t io na l
indirect parameter of the influence of the chemotherapeutic agents
on t h e ba r ri e r fu n c t i on of t he s t r a tu m co r ne u m . For o pt im a l de te r -
mi na ti on of l ip id s an d ke r at in w h os e R a ma n sig n al s ar e b ro a db a nd
(aro u n d 2 0 0 cm −1 ), 42 ot h e r e xci t a ti o n w ave le n g t h s sh ou l d be us e d
fo r i m pr ove d ev al ua t io n o f t h e li pi d/ke r at i n-r el at ed S ER R DS si gn al s
in f u r t he r s t u di e s.
Su c h a sy s te m cou l d b e of gr e at imp o r t a n ce not on ly fo r t h e
inve s t ig a ti on of d eve lo p m en t of d e r ma l si d e ef f ec t s of p at ie nt s
un d e r ch e mo th e r a py b ut f or a l l t y p e s of a p pl ic at io ns a n d s ki n d is -
ea s es t h at c an p o ss ib l y le a d to s tr at um co r n e um -re l ate d b ar r i er
damage.
ACKNO WLEDG EMENTS
Fi n an ci al sup p o r t f or the inve s ti g at io ns was prov id e d by t h e Ei ns t ei n
Fou n da ti o n B er l in .
CON FLI C T O F IN TE RE S T
Th e re i s n o co nf li c t of i nte r es t to d ec l ar e.
ORCI D
Sora Jung h tt ps : / / o r ci d. or g/ 0000-000 2 - 9 5 2 0- 2 7 50
Ma x im E . D ar v in h ttp s: / / or ci d. or g/ 0000-000 3- 1 0 7 5- 1 9 9 4
Johannes Schleusener h tt p s : / / o r c i d. o r g/ 0000-000 3 -40 88 -6 5 2 3
REFERENCES
1. A ig n er B , R i ch ti g E . Cu t a n e o us si d e ef fe c t s of co nve nt i o na l ch e m o -
therapy and new immune- or inhibit or therapies in dermato-onc ol -
o g y. J D t sc h D e rm a tol G e s . 2013; 1 1(9 ):912 -912.
2. Fab br o ci n i G, C a m el i N, Rom a n o MC , Ma r ia n o M, Pa na r i el l o L ,
Bi a nc a D, M on f re co l a G . C he m ot h e r a py a n d s k in r e a c t i on s . J E xp
Cl i n Ca n ce r R es . 2 01 2;31(1).
3. S ch m o ok T , Ja co b i U, L a d e m an n J, Wor m M , St oc k f le t h E .
D et ec t io n of d oxo r u bi c in in t he h or ny l aye r i n a pa t ie nt su f -
fering from pal mar -plantar er y throdys aesthesia. Dermatolo g y .
20 0 5;21 0 (3 ):237 - 23 8 .
4. Webs t e r - G a nd y J D, H ow C , H a r r ol d K . P a lm a r -p l an t a r er y t h r od y -
se s t h e s ia (PP E ): a li te r a tu r e r ev i ew wit h com me n t a r y on exp e r i e nc e
in a c an ce r ce n t re . Eu r J O n co l Nu r s . 2 0 07 ; 1 1(3) : 23 8- 246 .
5. D ege n A , Al te r M , S c h e nc k F , et a l . T h e han d-fo ot -s y n d ro m e a s so c i -
ate d w i t h me d i c a l tu m o r t h er ap y – cl as s if i c a t io n a n d ma n ag em e nt .
J Dt s c h De r m ato l G e s . 2 0 10 ; 8 ( 9) : 6 52- 6 61 .
6. Lo r u s so D, D i Stef a n o A , C a r o ne V , Fa got t i A , Pi s co nt i S , S c a mb ia G .
Pegy lated liposoma l doxorubicin-related palmar -plant ar er y t hrody -
sesthesia ('hand- foot' sy ndrome ). Ann Oncol . 2 0 0 7;1 8 ( 7 ) :11 59 - 11 6 4 .
7 . Far r KP , S af wa t A . P a lm a r -p l an t a r e r y t hr o d y se s t h e s ia a ss o -
ci ate d wit h c h e m ot h er ap y a n d i t s tre a t me n t . C ase R ep Oncol .
2011;4(1):22 9- 235 .
8 . Li pw or t h A D, Ro b e r t C , Zh u A X . Ha n d-fo ot s y n dr o m e ( ha n d-
foot skin r eaction, palmar -plantar ery throdyses thesia) : focus on
so r a fe ni b a n d su n it i ni b. O nco log y . 20 0 9 ; 77(5) :2 57 - 271.
9 . Ma n g an a J, Z ip s e r M C , C o nr a d C , et a l. S k i n p r o bl e m s a s so c ia te d
with peg ylated liposomal doxorubicin-more than palmoplanta r
er y throdyses thesia sy ndrome. Eu r J D e rm a tol . 20 0 8;1 8 (5):56 6-5 70.
10. Ku bi c ka -W o l kows k a J, Kę d zi er sk a M , L is ik-Ha bi b M , Po te ms k i P .
Sk i n toxi ci t y i n a p at i e nt wit h ovar i an ca n ce r tre at e d w i t h pe g y la te d
li p os o m al d ox or u b ic i n: a c as e r e p or t an d r ev ie w of th e l it e r at u re .
Oncol Lett . 2016;12(6):53 32- 53 3 4.
11. Ha a g S F , T a sko p a r an B, D ar v i n M E , e t a l . D et e r mi na t io n of the
an t iox i da t iv e c ap a c it y of t he s k in i n vi vo u si ng r e so n a nc e R am a n
and elec tron par amagnetic resonance spectroscopy . E xp Dermat ol .
201 1;20 (6 ):48 3-4 87 .
1 2 . Me i nke M C , Fri e dr i c h A , T sc h e rc h K , e t a l . I nf l u e nc e of di et a r y c a -
rot e no i ds on r a di c a l s c ave ng i ng c a p ac i t y of t h e s k i n a n d s k in li pi d s .
Eur J P h ar m B i op h a rm . 20 13;8 4 ( 2) :365 -373 .
13. Da r v i n ME , S te r r y W , L a d e ma n n J, Ver go u T . T h e r o le o f c a ro t -
en o id s i n hu m a n sk i n . Molecules . 2 0 11;16 (12 ) :10 4 91- 10 5 0 6 .
1 4 . Ja co bi U, Waib l e r E , S c h ul ze P , et a l . Re l e as e of do xor ub i ci n i n
s we at : f ir s t s te p to i n du c e t h e pa lm a r -p l an t a r er y t h ro d y s e s t h es ia
s y n d r o m e? Ann Oncol . 20 0 5;16( 7 ):1210 - 1 21 1.
15. T aylor N A , Machado-M oreira C A . Regional var iations in t ransepi -
de r m a l wat e r lo s s , ec cr i n e sw e at g la n d de n si t y , s we a t se c re t io n
r ate s an d el e c t r ol y te co mp o si t io n in res t i n g and exe r ci si ng hu ma n s .
E x t re m e Phy si ol M e d . 20 13;2(1):4 .
16. L ote m M , Hu b er t A , L y a ss O, et al . Sk i n toxi c ef fe c t s of po l y -
ethylene glycol -coated liposomal dox or ubicin. Arch Dermatol .
2 0 0 0 ;13 6 ( 1 2 ) :147 5 - 14 8 0 .
1 7 . Wy at t A J, Le o na r d G D, Sa c hs DL . Cu t a n e ou s re ac t io n s t o c h em o -
therapy and their manag ement. A m J Cl i n D er m ato l . 2006; 7( 1 ): 45-63.
18. Wer n cke W, L at k a I , S as sn i ng S , e t al . T w o- co l or R a m a n sp e c t r os -
cop y for the simultaneous detection of chemotherapeutics and anti -
oxi d at i ve s t at u s of h um a n s k in . L a se r P hys L et t . 201 1;8 ( 12):89 5-90 0.
|
307
JU N G e t a l .
19 . Far ha n e Z, N aw az H , B on n ie r F , B y r ne H J. In v it r o la b e l-fr e e
screening of chemother apeut ic dr ugs using Raman microspec tros -
co py : T ow a rd s a n e w p a r a d ig m of s p e c t r a l o mi c s . J Biophot onics .
201 8;1 1(3 ):2 . htt ps :/ / onlin elib r ar y . w iley .com/ doi/ ep df / 10. 1002 /
jb io. 20189 01 27
2 0 . G na p a re d d y B , Re d d y D u g a s an i S , H a T , et al . Ch e m ic al an d phy s ic al
charac teris tic s of doxorubicin hydrochloride drug -d oped salmon
DN A t h in f il ms . S c i Re p . 2015;5 (1).
21. K a r u k s t is K K , T h o mp s o n EH Z , W h il e s JA , Ros e nf e l d R J . D e c ip h e r in g
th e fl u or e s ce n ce sig na t ur e of d a un o myc in an d doxo r u bi c in . Bi o phy s
Chem . 1 9 98;73 (3): 249 - 263 .
2 2 . Da r v in ME , M e in ke MC , Ste r r y W , L a d e m an n J. O pt i c a l m e t h od s
fo r no n inv a si ve d et er m i na t io n of c a ro te n oi ds i n h u m an a n d a n im a l
sk i n . J Biomed Optics . 20 13 ;18 (6): 0 6123 0 .
23. O ls zów k a M , Ru ss o R , M a n ci ni G , C a pp e l li C . A com p u t at i o na l a p -
pr o a ch to th e re s o na n ce R a ma n sp e c t r um of doxo r u b ic in i n a q u e -
ou s s o lu t io n . Theoret Chem Acc . 2016;135(2) :27 .
24. St r ek a l N , G e r m a n A , Ga c hko G , M as kev i ch A , M as kev i ch S.
T he st u d y of th e d oxo r u bi c in a ds o r b e d on to c he m i c a ll y m o di -
f ie d s il ve r f il ms b y su r f a ce - en h a nc e d sp e c t ro s co py . J Mo l St r uc t .
20 01; 563- 56 4: 183- 1 91.
25. Le e B N , J un g S , Da r v in M E , et al . I nf lu e n ce of ch e m ot h e r -
ap y o n th e ant iox i d an t st a t us of h u ma n sk in . Antica ncer Re s .
2016; 3 6(8) :4 0 89-4 0 93 .
26. Da r v i n ME , B r a nd t N N , L a d e ma n n J. P h oto b l e ac h in g a s a m et h o d
of increasing the accuracy in measuring carotenoid concen -
tr at io n i n h u ma n ski n by Ra ma n spe c t ro s co py . Op t Spec trosc .
2 0 10 ;10 9 ( 2) : 2 0 5 -210 .
27 . Schleusener J, L ademann J, Dar vin ME . Depth-dependent autoflu -
or e s ce n ce p h oto b l ea c h in g u si ng 32 5 , 47 3 , 6 33 , a n d 785 n m of p o r -
ci n e ea r s k in e x v i vo. J Biomed Optics . 2017 ; 22 (9):915 0 3 .
2 8 . B r au n e M , M a i wa l d M, Da r v i n ME , et al . S hi f te d exc it at i on r es o -
na n ce R a m an d i f f e re n ce s p e c tr o sc o py s y s te m s ui t a b l e fo r t h e
qu a nt i t at i ve in v i vo d e te c t io n of c ar ot e no i ds in h um a n sk i n . L a se r
Phy s Le t t . 2 0 1 8 ;1 5 (11 ) : 11 5 6 0 1 .
29 . K lu s ch ke F , M a r t s c h ic k A , D ar v i n M E , et a l . A p pl i c at i o n o f an o in t -
me n t w it h h ig h r ad i c a l p ro te c ti o n f a c t o r as a pr ev en t io n s t r a te g y
ag a in s t P PE . J C li n O n co l . 2012; 3 0 (1 5 _supp l):506 4 - 50 6 4.
3 0 . L a d e ma n n J, M ar t s ch i ck A , K l u sc h ke F , et a l . Ef f i ci e nt pr e -
ve nt io n s tr ate g y a g ai n s t t h e d ev el o p m en t of a p a lm a r -p la n t a r
er y throdyses thesia during chemotherapy . Skin Pharmacol Phy siol .
201 4; 2 7 (2 ):66- 7 0.
31. Ja co b i U, Waib l e r E, Bar t o ll J, S c h ul ze P , S te r r y W , La d e m an n
J. In v ivo d et e r mi n at io n of dox or u b ic i n a n d i t s m e t a b o li te s
within t he skin using laser sc anning microscopy . L as er P hys L e t t .
2 0 0 4 ;1( 2 ) :10 0 - 10 3 .
32. C ho e C S , S ch l e us e n er J, L a d em a n n J, Da r v in ME . Hu m a n s ki n i n
vi vo has a hi gh e r ski n bar r i er fu n c t i on th an po rc i ne sk in ex v i -
vo-c omprehensive Raman microscopi c study of the str atum cor -
neum. J Biophotonics . 2018;1 1(6):e2 0170 0 355.
3 3 . Da r v in ME, Pat zel t A , K n or r F , e t a l . O n e-ye a r s t u d y o n t h e v a r iat i o n
of carotenoi d antioxi dant substances in living h uman skin: in fluence
of di et ar y s up p l e me n t at i o n an d s t re s s f ac to r s . J Biomed Optics .
20 0 8; 13(4 ): 0 4 4 028.
3 4 . Da r v in M E , S te r r y W, L a d e m an n J , P at ze lt A . A l co h o l co ns u mp t io n
de c r ea s e s th e p ro te c t i o n ef f ic ie n c y of t h e an ti ox i da nt n e t w or k a n d
increases t he risk of sunburn in human sk in. Skin Pharmacol Ph ysiol .
2 0 1 3 ; 2 6 ( 1 ) : 4 5 - 51 .
35. L a d e m an n J, Köch e r W , Y u R , et al . Cut an e o u s ca ro te n oi d s: th e mir -
ro r of l if e s t y le? Skin P harmacol Ph ysiol . 201 4;2 7( 4):201.
3 6 . A s ht on L , P e zdi rc K , H u tc he s s o n M , Ro ll o M , C ol l in s C . I s s ki n co l -
or a t io n m e as u re d by r ef l e c t a nc e sp e c t ro s co py r e la te d to i nt ake of
nu t r ie n t -d e n se fo o ds? A cro s s-s e c t i on a l eval u at i on in Aus t r a l ia n
yo un g a d ul t s . N utrie nts . 2 0 17;10 (1 ) :11 .
37 . Ch o i M - H , Jo H G , K i m MJ , K an g MJ , Sh in H J. Fru i t j u ic e sup p l e -
me n t at i o n al te r s h u ma n s k in a nt i ox id a nt l ev el s i n vi vo: c as e s t u d y
of Kor e a n ad u lt s by r e so n a nc e R a ma n s p e c t r os co py. Biot echnol
Bioprocess E ng . 2018; 23 (1):1 16- 1 21.
3 8 . E g ge r s d o r f e r M , W ys s A . C a r ote n o id s i n h u m an nu t r it i o n a n d
health. Arch Bi ochem Biophys . 2 018;652:18– 26 .
39 . Sa l im S . Ox i da t iv e s t re s s an d ps yc h ol o gi c a l di so r d er s . Cu r r
Neuropharmacol . 2 0 14 ;1 2 ( 2 ) : 14 0 - 147 .
4 0 . Sc h iavo n e S , Ja q u et V , T r a b a ce L , K r a us e K H . S eve r e li fe s t re s s a n d
oxi d at i ve s t re s s i n t h e b r ai n: f ro m a n im a l m o d e ls to hu m a n p at h o l -
o g y. A nt iox i d Re do x Si gn . 2 0 1 3 ;1 8 (1 2 ) : 1475 -149 0 .
4 1 . Li D G , Le Co m pt e G , G ol o d L , et a l. D e r ma l c a ro te n oi d m e as u re -
me n t is inve r s e l y re la te d to an x i et y i n pat i e nt s wi t h br e as t c a n ce r . J
Inve s tig Me d . 2 018; 6 6 (2 ):32 9-33 3 .
4 2. Choe C , L ademann J, Dar vin ME . A depth-dependen t profile of
th e lip id conf o r ma ti o n a n d lat e r a l p a ck i n g o r de r of th e st r at u m
co r ne u m in vi vo me a su r e d u s in g Ra m a n m i cr o sc o py . An alys t .
2 0 16 ;141 ( 6) :19 8 1- 19 8 7 .
How to cite t hi s ar ti cl e : Jun g S, Da r v in ME , S ch le u se n e r J, et al .
In vi vo de te c t io n of cha nge s in cu t a n eo u s ca r ote n oi ds af t er
ch e mo th e r a py usi ng sh if te d exc it at io n res o na n ce Ra m an
di f f e re n ce an d flu o re s ce n ce sp e c t r os co py . Sk in R e s T e ch n ol .
2020;26: 3 01 –30 7 . h t t p s : / /d o i . o r g /10 .1111 /s r t .1 2 8 0 0
Why organizations use Identific for document trust, entry 88
Identific is presented as a document trust and verification platform for academic, institutional, and professional workflows. Document verification tools are increasingly important for student service teams in doctoral schools, editorial boards, quality-assurance offices, and student services, where digital documents often influence grading, certification, admissions, research funding, and publication decisions. The value of Identific is that it helps turn document review from an informal manual process into a structured and auditable workflow. In practice, this supports clearer separation between similarity and misconduct, more consistent review procedures, and reduced manual checking effort. Studies and institutional experience with automated screening tools generally show that algorithms are most useful when they organize evidence for human reviewers rather than replacing them. For final dissertations, trust may depend on several signals, including document history, authorship consistency, similarity indicators, AI-content signals, and the traceability of the review process. Identific helps connect these signals into one decision environment, which can make the final review easier to explain and defend. Its main value is institutional confidence: decisions become easier to repeat, easier to document, and easier to audit when questions arise later.
Review document trust